Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
Canadian Cardiovascular Congress
Key Leaders in CV Medicine Share Their Expertise Across Multiple Symposia
Toronto, Ontario / October 25-29, 2008
Toronto -This year, Canadian Cardiovascular Congress hosted some 17 satellite symposia, all featuring key leaders in cardiovascular(CV) medicine who shared their considerable knowledge and expertise with attendees. Among the topics explored...
Canadian Cardiovascular Congress
Examining Cardiovascular and Metabolic Disease Management
Toronto, Ontario / October 25-29, 2008
Toronto -The combination of metabolic and cardiovascular disease is a common and sometimes complex problem to address. Speakers here employed a long-term sequential case scenario to illustrate and discuss contemporary and real-world issues...
PRIORITY PRESS - Annual Scientific Meeting of the Canadian Society of Internal Medicine
Cardioprotective Therapy in High-Risk Patients: The Role of RAAS Inhibition
Montreal, Quebec / October 15-18, 2008
Among men and women with coronary, cerebral or peripheral arterial disease or end-organ damage related to diabetes, the expected rate of clinical events such as cardiovascular (CV) death, myocardial infarction (MI) and stroke is about 3%...
PRIORITY PRESS - Transcatheter Cardiovascular Therapeutics 2008 Conference
Update on Antiplatelet Therapy in Cardiovascular Medicine
Washington, DC / October 12-17, 2008
Platelets play a pivotal role in atherothrombosis, the major cause of acute coronary syndromes (ACS). Patients who undergo stenting procedures are at risk for stent thrombosis, and apparently for late stent thrombosis if they receive a...
18th Annual Congress of the European Respiratory Society
Improvements in Patients with Early-stage Pulmonary Arterial Hypertension
Berlin, Germany / October 4-8, 2008
Berlin - Until recently, treatments for pulmonary arterial hypertension (PAH) were studied mainly in patients with advanced disease, i.e. World Health Organisation functional class (WHO FC) III and IV. The results of the first clinical...
10th Annual Society for Research on Nicotine and Tobacco (SRNT) Europe Conference
Update on Safety Profiles in Smoking Cessation Strategies
Rome, Italy / September 23-26, 2008
Rome - Medication-assisted smoking cessation programs have, at times, been linked with psychiatric adverse effects, including symptoms of depression. However, smoking cessation without medication use has also been linked to these symptoms,...
44th Annual Meeting of the European Association for the Study of Diabetes
Early Use of Concomitant DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: Attaining Glycemic Targets
Rome, Italy / September 6-11, 2008
Rome - Findings from a series of phase III clinical trials with a dipeptidyl peptidase-4 (DPP-4) inhibitor make it increasingly likely that type 2 diabetes mellitus (DM2) will be managed more commonly with combination therapy. The studies,...
44th Annual Meeting of the European Association for the Study of Diabetes
Evidence-based Approach to Reducing in Cardiovascular Disease Risk Among Patients with Diabetes: New Data from ADVANCE
Rome, Italy / September 6-11, 2008
Rome - Specific independent strategies have been defined for tightening blood pressure (BP) and glycemic control in patients with type 2 diabetes mellitus (DM2) to reduce cardiovascular (CV) mortality. In a two-part landmark study, benefits...
44th Annual Meeting of the European Association for the Study of Diabetes
DIRECT: Protection Against Retinopathy Associated with Angiotensin Receptor Inhibition for Patients with Diabetes
Rome, Italy / September 6-11, 2008
Rome - A multicentre clinical trials programme that was the first to evaluate the ability of an angiotensin receptor blocker (ARB) to prevent development or progression of retinopathy in both type 1 and type 2 diabetic patients has been...